Search

Your search keyword '"Coccorullo, Zaira"' showing total 11 results
Start Over Author "Coccorullo, Zaira"
11 results on '"Coccorullo, Zaira"'

8. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE

Author

Leo, Silvana, primary, Arnoldi, Ermenegildo, additional, Repetto, Lazzaro, additional, Coccorullo, Zaira, additional, Cinieri, Saverio, additional, Fedele, Palma, additional, Cazzaniga, Marina, additional, Lorusso, Vito, additional, Latorre, Agnese, additional, Campanella, Giovanna, additional, Ciccarese, Mariangela, additional, Accettura, Caterina, additional, Pisconti, Salvatore, additional, Rinaldi, Antonio, additional, Brunetti, Cosimo, additional, Raffaele, Mimma, additional, Coltelli, Luigi, additional, Spazzapan, Salvatore, additional, Fratino, Lucia, additional, Petrucelli, Luciana, additional, and Biganzoli, Laura, additional

Published
2018
Full Text
View/download PDF

9. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE.

Author

Leo, Silvana, Arnoldi, Ermenegildo, Repetto, Lazzaro, Coccorullo, Zaira, Cinieri, Saverio, Fedele, Palma, Cazzaniga, Marina, Lorusso, Vito, Latorre, Agnese, Campanella, Giovanna, Ciccarese, Mariangela, Accettura, Caterina, Pisconti, Salvatore, Rinaldi, Antonio, Brunetti, Cosimo, Raffaele, Mimma, Coltelli, Luigi, Spazzapan, Salvatore, Fratino, Lucia, and Petrucelli, Luciana

Subjects
BREAST cancer prognosis, ERIBULIN, ELDER care, GERIATRIC assessment, BREAST tumors, CANCER chemotherapy, CANCER relapse, MEDICAL cooperation, METASTASIS, SCIENTIFIC observation, QUALITY of life, QUESTIONNAIRES, RESEARCH, ACTIVITIES of daily living, TERMINATION of treatment, VISUAL analog scale, TREATMENT effectiveness, GERIATRIC Depression Scale, OLD age, THERAPEUTICS
Abstract

Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019
Full Text
View/download PDF

10. CA 19-9 Related Tumor Growth Rate After First Line Chemotherapy of Advanced Pancreatic Cancer

Author

Venturino Antonella, Coccorullo Zaira, Addamo Gianfranco, Colloca Giuseppe, Ratti Riccardo, Caltabiano Graziano, Guarneri Domenico, and Repetto Lazzaro

Subjects
Oncology, medicine.medical_specialty, business.industry, CA 15-3, Cancer, Hematology, medicine.disease, Chemotherapy regimen, Ca 19 9 antigen, Internal medicine, Pancreatic cancer, medicine, Tumor growth, CA19-9, First line chemotherapy, business
Published
2014

11. Docetaxel for metastatic breast cancer: two consecutive phase II trials.

Author

Campora E, Colloca G, Ratti R, Addamo G, Coccorullo Z, Venturino A, and Guarneri D

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Breast Neoplasms pathology, Docetaxel, Drug Administration Schedule, Female, Humans, Middle Aged, Neoplasm Metastasis, Young Adult, Antineoplastic Agents administration & dosage, Breast Neoplasms drug therapy, Taxoids administration & dosage
Abstract

Background: Docetaxel is the most active agent for metastatic breast cancer, but the optimal treatment regimen as a single agent has yet to be defined., Patients and Methods: Two consecutive monocentric phase II trials of docetaxel in metastatic breast cancer were carried out. In Trial I, 36 patients received docetaxel 35 mg/m2 weekly for 6 weeks every 8 weeks and in Trial II, 29 patients received docetaxel 100 mg/m2 day 1 every 21 days., Results: Patient characteristics were comparable. However, patients with liver involvement comprised 25% of cases in Trial I and 55% in Trial II. The overall response rate on an intention-to-treat basis was 19% vs. 45% in Trial I and II respectively; time to progression was 3.8 vs. 7.5 months respectively, and overall median survival was comparable in each trial., Conclusion: Docetaxel given at 100 mg/m2 every three weeks appears to be a safe, effective regimen that can be applied in common clinical practice for the treatment of metastatic breast cancer.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results